Holen Sie sich die Stockscreener-App
34.95
6.53%
2.22
Schlusskurs vom Vortag:
$32.73
Offen:
$33.885
24-Stunden-Volumen:
1.68M
Relative Volume:
0.16
Marktkapitalisierung:
$13.52B
Einnahmen:
$3.14B
Nettoeinkommen (Verlust:
$-3.36B
KGV:
-4.0034
EPS:
-8.73
Netto-Cashflow:
$-4.03B
1W Leistung:
+8.76%
1M Leistung:
+35.83%
6M Leistung:
-17.75%
1J Leistung:
-71.24%
1-Tages-Spanne:
$33.54
$35.59
1-Wochen-Bereich:
$30.88
$35.59
52-Wochen-Spanne:
$23.15
$125.68
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Vergleichen Sie MRNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
34.95 | 12.21B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.40 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.41 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.37 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
574.91 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.34 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Algorithm, Pipeline Analysis | IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode - Barchart.com
South Dakota Investment Council Lowers Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
What drives Moderna Inc. stock priceFree High-Return Strategy Alerts - jammulinksnews.com
Moderna (NASDAQ:MRNA) Given New $25.00 Price Target at Bank of America - MarketBeat
What analysts say about Moderna Inc. stockHigh-velocity gains - jammulinksnews.com
Moderna Inc. Stock Analysis and ForecastRapid profit acceleration - jammulinksnews.com
Moderna Target of Unusually High Options Trading (NASDAQ:MRNA) - MarketBeat
New York State Common Retirement Fund Sells 33,365 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Lexicography: Clear And Unequivocal - The National Law Review
Wealthfront Advisers LLC Purchases 18,268 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
After Moderna Pulled Its Shot, Combination Flu/COVID Vaccines Hang in Limbo - BioSpace
Moderna Bets Big On New Vaccines After Stock Tumbles - Finimize
Moderna, Inc. - Britannica
Equities Analysts Offer Predictions for Moderna Q2 Earnings - MarketBeat
Is Moderna Inc. a good long term investmentRobust investment performance - jammulinksnews.com
Edgestream Partners L.P. Has $2.78 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Buys 17,268 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Nisa Investment Advisors LLC - MarketBeat
Moderna, Inc. (MRNA) Aktienkurs, Nachrichten, Kurs und Verlauf - yahoo.co
Here's Why Moderna (MRNA) Fell More Than Broader Market - Yahoo Finance
Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know - Yahoo Finance
How IBM and Moderna’s partnership could lead to an explosion in drug development - Fast Company
Moderna cancels plans to build Japan plant on poor business environment - Reuters
Moderna gets full FDA approval for kids COVID-19 vaccine - MSN
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 26% - simplywall.st
Moderna cancels mRNA production plant in Japan (MRNA:NASDAQ) - Seeking Alpha
Cwm LLC Purchases 28,831 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Lobbying Update: $120,000 of MODERNA INC. lobbying was just disclosed - Quiver Quantitative
Thursday's Notable Option Activity: Oracle, United Airlines, Moderna - AInvest
How IBM and Moderna (MRNA) Are Using Quantum Computing to Design Vaccines Faster - TipRanks
Moderna to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025 - Amarillo Globe-News
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease - Knoxville News Sentinel
IBM-Moderna Showcase Quantum-Enhanced Drug Discovery - HPCwire
IBM and Moderna Team Up on Quantum Study. What It Means for the World of Medicine. - Barron's
Director, Strategic Forecasting, Oncology job with Moderna, Inc. | 1402245670 - New Scientist
Moderna’s latest approval again reveals FDA rift over COVID vaccines - BioPharma Dive
Bank of New York Mellon Corp Purchases 34,034 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
FDA Fully Approves Moderna’s COVID-19 Vaccine for Some Young Children - Vaccine Advisor
Lobbying Update: $100,000 of MODERNA US INC. lobbying was just disclosed - Quiver Quantitative
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.72%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):